Editas | GenomeWeb

Editas

The licenses cover IP related to a new CRISPR technology known as Cpf1, advanced forms of Cas9, and additional Cas9-based genome editing technologies.

Editas has paid $1 million to test-drive Adverum's viral vectors in clinical gene editing and $1 million for an option on an exclusive license.

The Massachusetts-based clinical gene editing firm has obtained exclusive rights to use the engineered Cas9 variants developed by one of its co-founders.

The deal sets up a multi-year collaboration on hematopoietic stem cell and T-cell editing with the San Raffaele Telethon Institute for Gene Therapy.

CFFT will support drug discovery and development for cystic fibrosis while Editas will look into both common and uncommon mutations.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.